Inceptor Bio enters into strategic relationships with the Principal Investigators and research institutions we partner with to form subsidiary companies in a hub and spoke model. The benefits are simple but significant:
Fastback Bio’s vision is to apply its novel technology platform to difficult-to-treat oncology indications. Focused on applying its novel co-stimulatory technology to T-cell therapeutics for the most difficult-to-treat tumors, from hematological malignancies to renal cell carcinoma, ovarian cancer, and triple-negative breast cancer. The technology was licensed from the University of North Carolina, Chapel Hill, where they continue to partner with the FastBack Bio team to drive this foundational innovation into reality for patients who so desperately need help.